Literature DB >> 18156936

Loss of heterozygosity of 17p13, with possible involvement of ACADVL and ALOX15B, in the pathogenesis of adrenocortical tumors.

Patsy S H Soon1, Rossella Libe, Diana E Benn, Anthony Gill, Janet Shaw, Mark S Sywak, Lionel Groussin, Xavier Bertagna, Christine Gicquel, Jerome Bertherat, Kerrie L McDonald, Stan B Sidhu, Bruce G Robinson.   

Abstract

OBJECTIVE: To determine the minimal common region of loss on 17p13 in a cohort of adrenocortical carcinomas (ACCs) (defined by a Weiss score > or =3) and adrenocortical adenomas (ACAs) (defined by a Weiss score <3) and subsequently to assess 3 genes in this region that could be involved in adrenocortical tumorigenesis. SUMMARY BACKGROUND DATA: Loss of heterozygosity (LOH) of 17p13 has been demonstrated to occur more frequently in ACCs compared with ACAs.
METHODS: Using 12 microsatellite markers across 17p13, LOH analysis was performed on 37 paired blood and adrenocortical tumor samples (23 ACC and 14 ACA samples) to determine the minimal common region of loss for ACCs and ACAs. From this minimal region of loss, 3 genes were selected for quantitative real time reverse transcription polymerase chain reaction analysis on 20 ACCs and 30 ACAs.
RESULTS: LOH at 17p13 was found in 74% of ACCs compared with 14% of ACAs. There was a 10.4-Mb common minimal region of loss in ACCs whereas no minimal region of loss in ACAs could be demonstrated. Expression of Acyl coenzyme-A dehydrogenase very long chain (ACADVL) and Arachidonate 15-lipoxygenase second type (ALOX15B) was significantly down-regulated in ACCs compared with ACAs whereas there was no difference in expression of Potassium channel tetramerization domain containing 11 (KCTD11) in ACCs and ACAs.
CONCLUSIONS: We demonstrated a minimal common region of loss of 10.4-Mb on 17p13 in ACCs and within this region, we found that ACADVL and ALOX15B expression are good discriminators between ACCs and ACAs.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18156936     DOI: 10.1097/SLA.0b013e318153ff55

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


  11 in total

Review 1.  Review paper: origin and molecular pathology of adrenocortical neoplasms.

Authors:  M Bielinska; H Parviainen; S Kiiveri; M Heikinheimo; D B Wilson
Journal:  Vet Pathol       Date:  2009-03       Impact factor: 2.221

2.  MicroRNA profiling of adrenocortical tumors reveals miR-483 as a marker of malignancy.

Authors:  Erin E Patterson; Alisha K Holloway; Julie Weng; Tito Fojo; Electron Kebebew
Journal:  Cancer       Date:  2010-11-08       Impact factor: 6.860

3.  The role of microRNA deregulation in the pathogenesis of adrenocortical carcinoma.

Authors:  Deniz M Özata; Stefano Caramuta; David Velázquez-Fernández; Pinar Akçakaya; Hong Xie; Anders Höög; Jan Zedenius; Martin Bäckdahl; Catharina Larsson; Weng-Onn Lui
Journal:  Endocr Relat Cancer       Date:  2011-10-27       Impact factor: 5.678

Review 4.  The role of lipoxygenases in pathophysiology; new insights and future perspectives.

Authors:  Ryuichi Mashima; Torayuki Okuyama
Journal:  Redox Biol       Date:  2015-08-07       Impact factor: 11.799

5.  Single nucleotide polymorphism array profiling of adrenocortical tumors--evidence for an adenoma carcinoma sequence?

Authors:  Cristina L Ronchi; Silviu Sbiera; Ellen Leich; Katharina Henzel; Andreas Rosenwald; Bruno Allolio; Martin Fassnacht
Journal:  PLoS One       Date:  2013-09-16       Impact factor: 3.240

Review 6.  Diagnostic and prognostic features in adrenocortical carcinoma: a single institution case series and review of the literature.

Authors:  Kerollos N Wanis; Rani Kanthan
Journal:  World J Surg Oncol       Date:  2015-03-24       Impact factor: 2.754

7.  Intra-tumor heterogeneity in TP53 null High Grade Serous Ovarian Carcinoma progression.

Authors:  Alba Mota; Juan Carlos Triviño; Alejandro Rojo-Sebastian; Ángel Martínez-Ramírez; Luis Chiva; Antonio González-Martín; Juan F Garcia; Pablo Garcia-Sanz; Gema Moreno-Bueno
Journal:  BMC Cancer       Date:  2015-11-30       Impact factor: 4.430

8.  Current management options for recurrent adrenocortical carcinoma.

Authors:  Anthony R Glover; Julian C Y Ip; Jing Ting Zhao; Patsy S H Soon; Bruce G Robinson; Stan B Sidhu
Journal:  Onco Targets Ther       Date:  2013-06-06       Impact factor: 4.147

9.  In silico analysis identifies genes common between five primary gastrointestinal cancer sites with potential clinical applications.

Authors:  Subhankar Chakraborty
Journal:  Ann Gastroenterol       Date:  2014

10.  Role of Scaffold Protein Proline-, Glutamic Acid-, and Leucine-Rich Protein 1 (PELP1) in the Modulation of Adrenocortical Cancer Cell Growth.

Authors:  Arianna De Luca; Paola Avena; Rosa Sirianni; Adele Chimento; Francesco Fallo; Catia Pilon; Ivan Casaburi; Vincenzo Pezzi
Journal:  Cells       Date:  2017-11-07       Impact factor: 6.600

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.